AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27824913
Drug: Delays in
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delays in AED administration from seizure onset
Trial: 25458644
Drug: Pioglitazone (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (titrated from 15 to 45 mg/d)
Trial: 18833867
Drug: Nesiritide (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nesiritide (0.01 mcg/kg/min) in addition to maximal standard therapy
Trial: 18833867
Drug: Maximal standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal standard therapy
Trial: 12185153
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with lofepramine 70 mg and L-phenylalanine 500 mg twice daily, plus vitamin B-12 1 mg intramuscularly weekly.
Trial: 12185153
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo tablets) plus vitamin B-12 1 mg intramuscularly weekly.
Trial: 8908233
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ketorolac IV before surgery
Trial: 6851412
Drug: Pentobarbital (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital (200 to 900 mg)
Trial: 26537365
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose beetroot juice (H-BT; 250 ml)
Trial: 26537365
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose beetroot juice (L-BT; 125 ml)
Trial: 26537365
Drug: Isocaloric placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric placebo (PLA; 250 ml)
Trial: 24898304
Drug: Albiglutide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide (30 mg, titrated to 50 mg)
Trial: 24898304
Drug: Glimepiride (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (2 mg, titrated to 4 mg)
Trial: 19442968
Drug: Cyclic user
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic user group receiving low-dose, monophasic OC pills for 24 months
Trial: 19442968
Drug: Continuous user
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous user group receiving low-dose, monophasic OC pills for 24 months
Trial: 19442968
Drug: Nonuser group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonuser group receiving no therapy
Trial: 15774699
Drug: Endotracheal 13C-labeled
RxNorm normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Endotracheal 13C-labeled dipalmitoyl phosphatidylcholine administration
Trial: 15177063
Drug: Primidone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primidone (500 mg daily)
Trial: 10457295
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (10 mg/kg/day once daily)
Trial: 10457295
Drug: Cefixime (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (10 mg/kg/day divided twice daily)
Trial: 10457295
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (azithromycin, cefixime, no antibiotics)
Trial: 1763537
Drug: Felodipine 5-40
RxNorm normalized name: felodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5-40 mg/d
Trial: 6762118
Drug: 8.33 g/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.33 g/h of glucose during 6 hours
Trial: 6762118
Drug: 16.66 g/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16.66 g/h of glucose during 6 hours
Trial: 6762118
Drug: 16.66 g/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16.66 g/h of glucose with 20 mu insulin
Trial: 6762118
Drug: 16.66 g/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16.66 g/h of glucose with 40 mu insulin
Trial: 28694687
Drug: VApal ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VApal ophthalmic solution (500 IU/mL)
Trial: 25750345
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg ibandronate i.v.
Trial: 25750345
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg zoledronic acid i.v.
Trial: 19346816
Drug: Randomized phase
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized phase II trial and randomized discontinuation trial
Trial: 17326546
Drug: 8 CBT
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8 CBT sessions (weekly)
Trial: 17326546
Drug: No-treatment waiting
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment waiting period (WL)
Trial: 15184276
Drug: Carvedilol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (50 mg/d) for 11 days
Trial: 15184276
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate (190 mg/d) for 11 days
Trial: 15184276
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate (190 mg/d)
Trial: 12375800
Drug: Etoposide/cisplatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide/cisplatin therapy
Trial: 7866846
Drug: 0.5 cc
RxNorm normalized name: SureComfort Pen 30g, 0.5 cc, 5/16 inches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 cc of dye (Telebrix N, 30 g)
Trial: 7866846
Drug: 1.0 cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 cc of dye (Telebrix N, 30 g)
Trial: 7866846
Drug: 2.0 cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 cc of dye (Telebrix N, 30 g)
Trial: 2503570
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of diflunisal given preoperatively
Trial: 2503570
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of paracetamol (2 doses: preoperatively and 4 h postoperatively)
Trial: 2503570
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (diflunisal and paracetamol)
Trial: 346616
Drug: Halofenate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofenate treatment
Trial: 30853151
Drug: IVIG plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG plus ciclosporin (5 mg/kg per day for 5 days)
Trial: 30853151
Drug: IVIG (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (conventional treatment)
Trial: 28025945
Drug: SpinalonTM (10-35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SpinalonTM (10-35 mg buspirone/100-350 mg levodopa/25-85 mg carbidopa)
Trial: 25845225
Drug: Flunarizine Hydrochloride
RxNorm normalized name: flunarizine hydrochloride
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine Hydrochloride Capsules (5 mg, twice daily for 5 days, then for two weeks in subsequent cycles)
Trial: 25845225
Drug: Flunarizine Hydrochloride
RxNorm normalized name: flunarizine hydrochloride
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine Hydrochloride Capsules
Trial: 23527716
Drug: Nebulised 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised 9 mg sodium hyaluronate plus saline solution
Trial: 18462234
Drug: 4% icodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% icodextrin solution
Trial: 17342946
Drug: Step down
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step down procedure for comparing several treatments
Trial: 10193285
Drug: Dextromethorphan 27
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 27 mg capsules, two doses before operation and three doses in the first 24 h after operation
Trial: 10193285
Drug: Dextromethorphan 27
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 27 mg capsules
Trial: 3364636
Drug: nalbuphine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine 0.25 mg/kg
Trial: 29449879
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Processing Therapy (CPT)
Trial: 30137415
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment only
Trial: 21484769
Drug: anti-tumor necrosis
RxNorm normalized name: G 1 (anti-tumor agent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-tumor necrosis factor (anti-TNF) therapy
Trial: 25748864
Drug: anti-TNF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-TNF therapy
Trial: 14528961
Drug: Single-channel maximum
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-channel maximum likelihood (ML) classifier (T2W)
Trial: 11787477
Drug: β1-selective β-blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β1-selective β-blocker
Trial: 30457900
Drug: Midazolam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (3 mg/kg)
Trial: 30457900
Drug: Midazolam-butorphanol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam-butorphanol (3 mg/kg for each drug)
Trial: 30457900
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline (0.9% NaCl) solution (control treatment)
Trial: 24680549
Drug: Edoxaban 30mg
RxNorm normalized name: EDOXABAN 30MG TAB
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Edoxaban 30mg once daily
Trial: 24680549
Drug: Enoxaparin 2000IU
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 2000IU twice daily
Trial: 31351659
Drug: Cligosiban (400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cligosiban (400-800 mg, taken 1 to 6 hours prior to sexual activity)
Trial: 27502861
Drug: Bococizumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bococizumab (150 mg subcutaneously every 2 weeks)
Trial: 25158896
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (40 mg methylprednisolone acetate mixed with 0.5 ml of 2% lidocaine) after 2 monthly saline placebo injections.
Trial: 25158896
Drug: Dextrose injection
RxNorm normalized name: Dextrose Injection
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose injection (0.5 ml of 20% DX mixed with 0.5 ml of 2% lidocaine) repeated monthly for 3 months.
Trial: 19347940
Drug: Combined low/high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined low/high power laser therapy
Trial: 11440275
Drug: Plasma adrenomedullin
RxNorm normalized name: Adrenomedullin
DrugBank: Adrenomedullin (DB19102)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma adrenomedullin concentrations in patients with pheochromocytoma (37.9 +/- 6 pg/ml)
Trial: 9763725
Drug: Low-dose phenobarbital
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose phenobarbital given daily for 3-7 days in conjunction with malaria therapy (artesunate or quinine + tetracycline)
Trial: 9763725
Drug: Low-dose phenobarbital
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose phenobarbital with 5-day artesunate regimen
Trial: 9763725
Drug: Low-dose phenobarbital
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose phenobarbital with quinine-tetracycline regimen
Trial: 9763725
Drug: Low-dose phenobarbital
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose phenobarbital with dosing every 24 hours (artesunate)
Trial: 8311270
Drug: 70 mL
RxNorm normalized name: ALCOHOL 70 mL TOPICAL SWAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mL of 0.25% ropivacaine
Trial: 8311270
Drug: 70 mL
RxNorm normalized name: ALCOHOL 70 mL TOPICAL SWAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mL of 0.125% ropivacaine
Trial: 29592840
Drug: Doravirine 100
RxNorm normalized name: doravirine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine 100 mg once daily plus two NRTIs (tenofovir and emtricitabine or abacavir and lamivudine)
Trial: 29592840
Drug: Ritonavir-boosted darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted darunavir 800 mg plus two NRTIs (tenofovir and emtricitabine or abacavir and lamivudine)
Trial: 27988146
Drug: Procaine benzylpenicillin
RxNorm normalized name: Procaine benzylpenicillin
DrugBank: Procaine benzylpenicillin (DB09320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Procaine benzylpenicillin and gentamicin once a day for 7 days (reference treatment)
Trial: 27988146
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin twice daily and intramuscular gentamicin once a day for 7 days
Trial: 27988146
Drug: Procaine benzylpenicillin
RxNorm normalized name: Procaine benzylpenicillin
DrugBank: Procaine benzylpenicillin (DB09320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Procaine benzylpenicillin and gentamicin once a day for 2 days followed by oral amoxicillin twice daily for 5 days
Trial: 11297610
Drug: 22-kDa recombinant
RxNorm normalized name: Antihemophilic factor (recombinant), pegylated (20 kda)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22-kDa recombinant human GH (rhGH) at a dosage of 0.15 IU/kg/day for 1 week
Trial: 8311540
Drug: Diclofenac/misoprostol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac/misoprostol (50 mg/200 micrograms twice daily)
Trial: 8311540
Drug: Piroxicam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (10 mg twice daily)
Trial: 8311540
Drug: Naproxen (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (375 mg twice daily)
Trial: 30245114
Drug: Predictive scores
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive scores for NOMI based on risk factors identified (renal insufficiency, use of cardiopulmonary bypass, intra-aortic balloon pump support, reexploration for bleeding, renal replacement therapy, packed red blood cells ≥ 4 units)
Trial: 22555773
Drug: 1.4 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m2 eribulin mesylate alone
Trial: 22555773
Drug: 0.7 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mg/m2 eribulin mesylate plus 200 mg ketoconazole
Trial: 16150858
Drug: Exisulind 400
RxNorm normalized name: Exisulind
DrugBank: Exisulind (DB06246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exisulind 400 mg
Trial: 16150858
Drug: Exisulind 200
RxNorm normalized name: Exisulind
DrugBank: Exisulind (DB06246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exisulind 200 mg
Trial: 10898676
Drug: Abacavir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir monotherapy (200, 400, or 600 mg every 8 hours [TID] and 300 mg every 12 h [BID]) for 4 weeks
Trial: 10898676
Drug: Abacavir with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir with zidovudine (200 mg TID or 300 mg BID) for 8 weeks
Trial: 10898676
Drug: Abacavir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir (300 mg BID) with zidovudine
Trial: 1356527
Drug: Gonadotrophin releasing
RxNorm normalized name: Gonadotrophin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin releasing hormone (intranasally)
Trial: 23009186
Drug: Ketamine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine with adjunctive atropine
Trial: 23009186
Drug: Ketamine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine with adjunctive metoclopramide
Trial: 12132062
Drug: IV nefopam
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV nefopam 0.15 mg/kg in 10 mL saline
Trial: 12132062
Drug: IV tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tramadol 0.5 mg/kg in 10 mL saline
Trial: 11136320
Drug: Curative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curative treatment for recurrence
Trial: 3277562
Drug: Cefuroxime axetil,
RxNorm normalized name: Cefuroxime Axetil, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil, 250 mg orally every 12 hours
Trial: 3277562
Drug: Cefuroxime axetil,
RxNorm normalized name: Cefuroxime Axetil, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil, 500 mg orally every 12 hours
Trial: 3277562
Drug: Cefaclor, 500
RxNorm normalized name: Cefaclor, 500 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor, 500 mg orally every eight hours
Trial: 21572151
Drug: ETN 25
RxNorm normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETN 25 mg twice a week with 6‐8 mg/week MTX (E+M group)
Trial: 18288617
Drug: Rebamipide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide (100 mg t.i.d)
Trial: 8628335
Drug: Fish-oil preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil preparation (2.7 g of n-3 fatty acids daily)
Trial: 8628335
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (daily)
Trial: 8628335
Drug: Fish-oil preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil preparation
Trial: 29489721
Drug: 1.2 g·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g·kg‐1 LMW (maltodextrin/dextrose/fructose)
Trial: 29489721
Drug: 1.2 g·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g·kg‐1 HMW (Vitargo)
Trial: 29489721
Drug: 0.066 g·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.066 g·kg‐1 PLA (noncaloric flavoring)
Trial: 22393898
Drug: Bilastine 20
RxNorm normalized name: Bilastine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilastine 20 mg co-administered with ketoconazole 400 mg
Trial: 16670121
Drug: Pediacel vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediacel vaccine
Trial: 16670121
Drug: Diphtheria-tetanus-whole-cell pertussis-Haemophilus
RxNorm normalized name: DIPHTHERIA/HAEMOPHILUS/PERTUSSIS/POLIO/TETANUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria-tetanus-whole-cell pertussis-Haemophilus influenzae type b (DTwP-Hib) vaccine
Trial: 16670121
Drug: DTwP-Hib vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP-Hib vaccine
Trial: 15640461
Drug: Defatted rice
RxNorm normalized name: rice bran, defatted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defatted rice bran diet (13-22 g dietary fiber/d)
Trial: 12198012
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation of 80 mg Cu (as copper sulfate). kg body wt(‐1). d(‐1) for 15 d
Trial: 10192200
Drug: Interferon-alpha2a alone
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha2a alone (4.5 MIU thrice weekly for 6 months)
Trial: 10192200
Drug: Interferon-alpha2a plus
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha2a plus ribavirin (1000-1200 mg/day in combination with the same dose of interferon-alpha2a for 6 months)
Trial: 10192200
Drug: Interferon-alpha2a plus
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha2a plus ribavirin (1000-1200 mg/day)
Trial: 2129094
Drug: Prophylactic anticonvulsant
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic anticonvulsant therapy
Trial: 25282520
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg every 4 weeks for 12 weeks
Trial: 25350595
Drug: Local melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local melatonin (3 mg)
Trial: 23226013
Drug: Azithromycin taken
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin taken daily for one year
Trial: 8150847
Drug: Topical therapeutic
RxNorm normalized name: Moisturel Therapeutic Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapeutic ultrasound followed by 10 minutes of passive stretching
Trial: 8150847
Drug: Placebo ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ultrasound treatments and stretching
Trial: 3170408
Drug: met‐hGH (2.67
FDA approved: no
EMA approved: no
PMDA approved: no
Description: met‐hGH (2.67 mg/0.5 ml diluent, 3 days/wk)